%0 Journal Article
%A Garcia-Medina, Jose J
%A Benitez-Del-Castillo, Javier
%A Rodríguez-Agirretxe, Iñaki
%A Lopez-Lopez, Fernando
%A Moreno-Valladares, Antonio
%A VISIONARY Study Group (Spain)
%T Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain.
%D 2022
%U http://hdl.handle.net/10668/19702
%X Purpose: Data are presented from ophthalmology clinics in Spain participating in the VISIONARY study, examining the effectiveness, tolerability, and safety of the preservative-free tafluprost (0.0015%) and timolol (0.5%) fixed-dose combination (PF tafluprost/timolol FC) in the treatment of OAG and OHT. Methods: An observational, multicenter prospective study examined treatment outcomes following a switch to PF tafluprost/timolol FC in adult OAG/OHT patients demonstrating insufficient response to beta-blocker or prostaglandin analog (PGA) monotherapy. Primary end point was mean change in intraocular pressure (IOP) from baseline at month 6. Changes in the severity of ocular signs and symptoms were also assessed. Results: Overall, 92 patients (51.1% female) were included. Mean (standard deviation) age was 68.3 (12.1) years. Mean IOP was reduced from 21.9 mmHg at baseline to 16.7 mmHg at month 6 (22.3% decrease; P 
%K fixed-dose combination
%K ocular hypertension
%K open-angle glaucoma
%K preservative-free topical medication
%K tafluprost
%K timolol
%~